Highlights

  • Sigma Healthcare (ASX:SIG) delivered its first full financial year following the Chemist Warehouse merger.
  • FY26 Revenue and normalised Earnings recorded double-digit growth across the enlarged group.
  • Integration synergies are progressing, while domestic and international pharmacy operations continue to expand.
  • Future performance will depend on like-for-like sales, network growth, synergy delivery and disciplined Capital allocation.

Sigma Healthcare (ASX:SIG) has been transformed from a traditional pharmaceutical wholesaler into a much larger integrated retail and wholesale healthcare group following its combination with Chemist Warehouse.

The merger, completed in February 2025, gave public-market investors direct exposure to the Chemist Warehouse network while combining its retail reach with Sigma’s pharmaceutical distribution infrastructure.

The company’s FY26 result, released on 27 August 2026, provided the clearest evidence yet of how the enlarged Business is performing. Revenue reached $10.8 billion, up 15.5% on a normalised pro-forma basis, while normalised EBIT rose 20.6% to $1.09 billion.

First full year of the merged group

FY26 represented Sigma Healthcare’s (ASX:SIG) first full financial year following the Chemist Warehouse combination.

Normalised NPAT increased 22.3% to $732.3 million, while the normalised EBIT Margin improved to 10.1%. The result showed that earnings grew faster than revenue, indicating improving Operating Leverage across the enlarged platform.

The Australian segment remained the largest contributor, recording revenue growth of 14.9% and normalised EBIT growth of 18.3%.

International operations also strengthened materially, with segment EBIT rising 91.3% to $55.8 million. Ireland reached profitability for the first time, adding evidence that Sigma’s offshore network is beginning to contribute more meaningfully to group earnings.

Integration synergies gather pace

One of the most important tests of the Merger is whether the combined group can extract meaningful efficiencies from its larger operating base.

Sigma Healthcare (ASX:SIG) reported $32.6 million of integration synergies in FY26 and said it remained on track to deliver $100 million of annual synergies by FY29.

These savings matter because the merger thesis rests not only on combining two large healthcare businesses, but also on improving procurement, distribution, technology and operational efficiency.

If synergy delivery continues while sales expand, the enlarged group could generate further margin improvement without relying solely on new store openings.

Integration execution nevertheless remains important. Combining large retail, Franchise and wholesale operations creates operational complexity, and the benefits need to be delivered without disrupting service levels or partner relationships.

Network growth supports the retail story

Chemist Warehouse remains central to Sigma’s growth strategy.

The group now supports Australia’s largest franchised pharmacy network, approaching 900 pharmacies across Chemist Warehouse, Amcal and Discount Drug Stores. Sigma also operates internationally across New Zealand, Ireland, Dubai and China.

The strength of the Chemist Warehouse Brand provides the enlarged group with a significant consumer-facing platform, while Sigma’s wholesale infrastructure gives it scale further up the pharmaceutical Supply chain.

At the first half, Australian Chemist Warehouse branded store sales had risen 17.2%, with like-for-like sales growth of 15.0%, illustrating the momentum that carried into the full-year period.

Future like-for-like sales growth will remain one of the most useful measures of whether the existing store network continues to gain customer spend without relying entirely on additional outlets.

Balance sheet remains important

The combination has created a significantly larger group, making capital discipline increasingly important.

Sigma reported net Debt of $663 million at the end of FY26, with debt representing 0.57 times normalised EBITDA. Management characterised the Balance Sheet as conservatively leveraged.

That financial position gives the company some flexibility to continue investing in stores, supply-chain infrastructure and international growth while also progressing integration initiatives.

It also means future expansion does not necessarily need to depend on aggressive balance-sheet leverage.

The company’s decision in June 2026 not to proceed with a potential Acquisition of Boots also illustrated a willingness to step away from transactions that did not meet its strategic and capital requirements.

Why it matters

Sigma Healthcare (ASX:SIG) now combines several attractive healthcare characteristics within one platform: recurring pharmaceutical demand, a large consumer-facing retail network, wholesaling scale and international growth potential.

The merger has also changed the earnings profile materially. Chemist Warehouse provides exposure to retail growth, while Sigma’s wholesale operations create additional scale and supply-chain integration.

The FY26 result suggests the integration is beginning to translate into financial benefits rather than remaining purely a strategic proposition.

However, the company now needs to demonstrate that double-digit growth can be sustained as the merger moves beyond its initial integration phase.

Catalysts and risks to watch

Further synergy delivery will be one of the main catalysts. Progress toward the targeted $100 million annual benefit by FY29 would support the margin story.

Like-for-like Chemist Warehouse sales, new pharmacy additions and international network growth will also remain important indicators.

International profitability is another area to monitor following the improvement in FY26, particularly whether Ireland and other offshore markets can make a larger contribution over time.

The main risks include integration complexity, slower retail sales growth and regulatory changes affecting pharmacy economics.

Australian pharmacy operators remain exposed to government policy through the Pharmaceutical Benefits Scheme and community pharmacy funding arrangements.

Competition is another consideration. Sigma must maintain the value proposition of Chemist Warehouse while balancing Franchisee economics, wholesale relationships and supplier dynamics.

International expansion also carries execution risk, particularly as the group moves into markets with different regulatory and competitive environments.

The bottom line

Sigma Healthcare (ASX:SIG) has moved beyond the initial merger narrative and into the execution phase of its transformation.

FY26 delivered $10.8 billion of revenue, $1.09 billion of normalised EBIT and $732.3 million of normalised NPAT, while integration synergies and international earnings continued to build.

The next stage will be about proving that these gains can persist. Continued like-for-like sales growth, successful network expansion, disciplined capital allocation and further synergy delivery would strengthen the case that the Chemist Warehouse combination has created a more scalable healthcare platform.